524715 Stoklara Genel Bakış Bir jenerik ilaç şirketi olan Sun Pharmaceutical Industries Limited, Hindistan'da ve uluslararası alanda markalı ve jenerik formülasyonlar ve aktif farmasötik bileşenler (API'ler) geliştirmekte, üretmekte ve pazarlamaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Sun Pharmaceutical Industries Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Sun Pharmaceutical Industries Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı ₹1,861.70 52 Haftanın En Yüksek Seviyesi ₹1,960.20 52 Haftanın En Düşük Seviyesi ₹1,252.65 Beta 0.60 1 Aylık Değişim 6.41% 3 Aylık Değişim -4.47% 1 Yıllık Değişim 47.75% 3 Yıllık Değişim 120.22% 5 Yıllık Değişim 318.92% Halka arzdan bu yana değişim 23,922.00%
Son Haberler & Güncellemeler
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20 Daha fazla güncelleme görün
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20
Sun Pharma Introduces Novel Treatment, Tedizolid Phosphate in India for Acute Bacterial Skin and Skin Structure Infection Aug 23
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2023-2024 Aug 06
Price target increased by 7.0% to ₹1,749 Aug 05
Price target increased by 7.2% to ₹1,746 Aug 04
Sun Pharmaceutical Industries Limited Receives Approval from U.S. Food and Drug Administration for LEQSELVITM (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata Jul 26
Sun Pharmaceutical Industries Limited to Report Q1, 2025 Results on Aug 01, 2024 Jul 16
Full year 2024 earnings: EPS exceeds analyst expectations Jul 10
Upcoming dividend of ₹5.00 per share Jul 05
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately Jun 25
Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults Jun 24
Sun Pharmaceutical Industries Limited, Annual General Meeting, Aug 05, 2024 Jun 20
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million. Jun 08
Full year 2024 earnings: EPS exceeds analyst expectations May 23
Sun Pharmaceutical Industries Limited to Report Q4, 2024 Results on May 22, 2024 May 15
Sun Pharmaceutical Industries Limited Announces Executive Changes Apr 03
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million. Feb 20
Dividend increased to ₹8.50 Feb 02
Price target increased by 9.3% to ₹1,453 Feb 01
Third quarter 2024 earnings: EPS exceeds analyst expectations Feb 01
Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024 Jan 31
Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024 Jan 16
Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm Dec 13
Sun Pharmaceutical Industries Limited Announces Management Changes Dec 07
Second quarter 2024 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023 Oct 14
Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Oct 13
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million. Oct 06
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million. Sep 29
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023 Aug 30
Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023 Aug 29
Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries Aug 28
Price target increased by 7.0% to ₹1,229 Aug 07
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Jul 30
Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV® Jul 24
Upcoming dividend of ₹4.00 per share at 1.0% yield Jul 21
High number of new directors Jul 18
Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023 Jul 12 Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023
Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited Jul 03
Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne Jun 27
Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions Jun 26
Full year 2023 earnings: Revenues and EPS in line with analyst expectations May 27 Sun Pharmaceutical Industries Limited Announces Board Appointments
Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023 May 12
Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update May 04
Whole Time Director recently sold ₹3.9m worth of stock Mar 22
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion. Feb 20
Sun Pharmaceutical Industries Limited Announces US FDA Approval for Generic Lenalidomide Capsules Feb 11
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 01 Sun Pharmaceutical Industries Limited Announces Retirement of Kalyanasundaram Subramanian as Whole-Time Director, Effective February 13, 2023
Sun Pharmaceutical Industries Limited Launches SEZABYTM (Phenobarbital Sodium) in the U.S. for the Treatment of Neonatal Seizures Jan 26
Sun Pharmaceutical Industries Limited to Report Q3, 2023 Results on Jan 31, 2023 Jan 17
Sun Pharmaceutical Industries Limited Announces One of Its Wholly-Owned Subsidiaries Launch A Novel Anti-Cancer Drug, Palbociclib in India for Patients Jan 12
Aurinia Pharmaceuticals Inc. Enters into Settlement Agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE Jan 04
Whole Time Director recently sold ₹9.2m worth of stock Dec 28
Insider recently sold ₹3.1m worth of stock Dec 10
Whole Time Director recently sold ₹10m worth of stock Nov 27
Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures Nov 19
Second quarter 2023 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited Approves the Appointment of Sanjay Asher as an Additional Director Designated as an Independent Director Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2023 Results on Nov 01, 2022 Oct 11
Whole Time Director recently sold ₹14m worth of stock Sep 24
Upcoming dividend of ₹3.00 per share Aug 12
Sun Pharmaceutical Industries Limited Announces Retirement of Israel Makov as Chairman and Member of the Board Aug 05 Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year 2021-22, Payable on or Before September 20, 2022
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 30
Sun Pharmaceutical Industries Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 13
Sun Pharmaceutical Industries Limited Announces Cessation of Mr. Ashok I Bhuta as Compliance Officer Jun 02
Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year Ended March 31, 2022 May 31
Full year 2022 earnings: EPS misses analyst expectations May 31
Sun Pharmaceutical Industries Limited to Launch Brillo® in India May 19
Sun Pharmaceutical Industries Limited to Report Q4, 2022 Results on May 30, 2022 May 16
Executive Director recently sold ₹1.8m worth of stock Apr 03
Executive Director recently sold ₹14m worth of stock Mar 23 Sun Pharmaceutical Industries Limited Announces Change of Company Secretary and Compliance Officer
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 01
Sun Pharma Receives DCGI Approval for Molxvir® (Molnupiravir) in India Dec 29
Whole Time Director recently sold ₹4.0m worth of stock Dec 28
A Federal Judge Denies All Motions for Summary Judgment in a Lawsuit Against Sun Pharmaceutical Industries Ltd and Ranbaxy Inc. in Generic Drug Overpricing Lawsuit Nov 24
Second quarter 2022 earnings released: EPS ₹8.50 (vs ₹7.56 in 2Q 2021) Nov 03
Whole Time Director recently sold ₹45m worth of stock Oct 03
Sun Pharma Launches Chericof® 12 in India, A Novel Formulation That Provides Relief from Cough for Up to 12 Hours Sep 30
Insider recently sold ₹167k worth of stock Sep 22
Non-Executive & Independent Director Vivek Sehgal has left the company Sep 08
Upcoming dividend of ₹2.00 per share Aug 16
Insider recently sold ₹1.0m worth of stock Aug 12
Price target increased to ₹826 Aug 03 Hissedar Getirileri 524715 IN Pharmaceuticals IN Pazar 7D 2.9% 1.7% 0.2% 1Y 47.8% 39.1% 17.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 524715 geçen yıl % 39.1 oranında getiri sağlayan Indian Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: 524715 geçen yıl % 17.2 oranında getiri sağlayan Indian Piyasasını aştı.
Fiyat Oynaklığı Is 524715's price volatile compared to industry and market? 524715 volatility 524715 Average Weekly Movement 2.5% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: 524715 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 524715 'nin haftalık oynaklığı ( 2% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir jenerik ilaç şirketi olan Sun Pharmaceutical Industries Limited, Hindistan'da ve uluslararası alanda markalı ve jenerik formülasyonlar ve aktif farmasötik bileşenler (API'ler) geliştirmekte, üretmekte ve pazarlamaktadır. Şirket, merkezi sinir sistemi, dermatoloji, kardiyoloji, onkoloji, nöropsikiyatri, gastroenteroloji, anti-enfektifler, diyabetoloji, ağrı/analjezikler, vitaminler/mineraller/besinler, solunum, jinekoloji, üroloji, oftalmoloji, ortopedi, nefroloji, dişçilik ve diğer alanlar dahil olmak üzere çeşitli terapötik alanlarda formülasyonlar sunmaktadır. Anti-kanserler, peptidler, steroidler, hormonlar ve immünosupresan ilaçlar için API'ler sağlamaktadır.
Daha fazla göster Sun Pharmaceutical Industries Limited Temel Bilgiler Özeti Sun Pharmaceutical Industries'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 524715 temel i̇stati̇sti̇kler Piyasa değeri ₹4.47t Kazançlar(TTM ) ₹110.54b Gelir(TTM ) ₹503.08b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 524715 gelir tablosu (TTM ) Gelir ₹503.08b Gelir Maliyeti ₹112.67b Brüt Kâr ₹390.41b Diğer Giderler ₹279.87b Kazançlar ₹110.54b
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) 46.07 Brüt Marj 77.60% Net Kâr Marjı 21.97% Borç/Özkaynak Oranı 3.0%
524715 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün Temettüler
0.7% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/27 06:01 Gün Sonu Hisse Fiyatı 2024/12/27 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2024/03/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Sun Pharmaceutical Industries Limited 73 Bu analistlerden 36, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Nitin Bhasin Ambit Capital Prashant Nair Ambit Capital null null Anand Rathi Shares and Stock Brokers Limited
Göster 70 daha fazla analist 
